Dyax (DYAX) Higher After Competing Drug Fails to Hit Endpoint
More News related to DYAX
- DX-88 (ecallantide) Demonstrated Relief of Symptoms in Hereditary Angioedema Acute Attacks in All Attack Locations
- National Securities Initiates Coverage on Dyax (DYAX) with a Buy
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Dyax Corp. (DYAX) Posts Q3 Loss of $0.17, Wider Than Expected
- Dyax Corp. Announces Third Quarter 2009 Financial Results
Dyax Corp. (Nasdaq: DYAX) is 15% higher in after-hours action. According to a representative from the company, a competing drug for hereditary angioedema (HAE) from Jerini (www.jerini.com) did not meet its primary endpoint in one of two pivotal Phase III trials (FAST-1)
Dyax's lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. In its joint venture with Genzyme Corporation, Dyax has successfully completed three Phase II trials of DX-88 for the treatment of hereditary angioedema (HAE). A Phase III trial is ongoing.
Related Categories
FDAHot List
Stocks Mentioned
+0.26Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
